Corcept Therapeutics
CORT
CORT
422 hedge funds and large institutions have $5.87B invested in Corcept Therapeutics in 2025 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 155 increasing their positions, 157 reducing their positions, and 65 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
36% less capital invested
Capital invested by funds: $9.24B → $5.87B (-$3.37B)
39% less call options, than puts
Call options by funds: $51.5M | Put options by funds: $84.9M
63% less funds holding in top 10
Funds holding in top 10: 16 → 6 (-10)
Holders
422
Holding in Top 10
6
Calls
$51.5M
Puts
$84.9M
Top Buyers
| 1 | +$65M | |
| 2 | +$59.4M | |
| 3 | +$55.5M | |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$41.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$30.3M |
Top Sellers
| 1 | -$156M | |
| 2 | -$64.8M | |
| 3 | -$51M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$31.5M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$31.4M |